Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies
October 28, 2025, 9:33 pm
Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB-002 for Von Willebrand Disease and sutacimig for Glanzmann thrombasthenia, pushing both towards crucial registration studies. Led by Sofinnova Partners, the oversubscribed round includes major global asset managers and sovereign wealth funds. Hemab plans pipeline expansion, including HMB-003, solidifying its ambition to build the definitive "clotting company." This investment promises transformative prophylactic therapies, addressing profound unmet patient needs across rare bleeding conditions. It signals a new era for advanced treatments.
Hemab Therapeutics announced a monumental $157 million Series C financing. This substantial funding propels the clinical-stage biotechnology company forward. It targets severe, underserved bleeding and thrombotic disorders. The round signals strong investor confidence in Hemab’s innovative pipeline.
Sofinnova Partners spearheaded the oversubscribed financing. A large long-only global asset management company also participated. New investors included a major global sovereign wealth fund and Avoro Capital Advisors. Existing investors reaffirmed their commitment. These included RA Capital Management, Novo Holdings, Access Biotechnology, and Deep Track Capital. HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital also contributed.
This strategic investment brings new leadership. Joe Anderson, PhD, Partner at Sofinnova Partners, joins Hemab’s Board. His expertise will guide the company’s trajectory. Benny Sorensen, MD, PhD, leads Hemab as CEO. He steers a company focused on novel prophylactic therapeutics. These solutions aim to transform treatment for patients facing significant unmet needs.
The immediate focus for the new capital is clear. Hemab will advance HMB-002. This program targets Von Willebrand Disease (VWD). The goal is to move HMB-002 towards registration studies. HMB-002 is an antibody-based treatment. Phase 1 data showed a clear mechanism of action. It directly addresses VWD’s underlying pathophysiology. It increases both Von Willebrand Factor and Factor VIII levels. This offers a novel approach, moving beyond symptom management.
Another critical program, sutacimig, will also benefit. Sutacimig treats Glanzmann thrombasthenia (GT). This rare disorder can be life-threatening. Hemab develops sutacimig as the first prophylactic therapy for GT. Promising Phase 2 results support its potential. The company plans a registration study in 2026. Further expansion into a Phase 2 study for Factor VII deficiency is also planned.
Hemab is not just advancing existing therapies. The company aims for broader pipeline expansion. It intends to introduce additional drug candidates. HMB-003 is one such program. Its announcement is expected in the first half of 2026. This reflects a commitment to a diverse portfolio. Hemab’s mission is to deliver innovative, durable treatment options.
The company’s development programs are deeply informed by patient experience. Hemab conducts natural history studies: GT360, FVIID360, and VWD360. These studies provide crucial insights. They reveal the profound physical and emotional burdens of chronic bleeding disorders. Such conditions have long lacked effective prophylactic therapies. Hemab’s approach is rooted in understanding these patient needs.
This significant funding round validates Hemab’s scientific rigor. It underscores its patient-centric approach. The biotech firm is building what it calls "the ultimate clotting company." This ambition involves leveraging unprecedented domain expertise in clotting science. It combines this with proven capabilities in drug development. From early stages to approval and commercialization, Hemab’s team brings extensive experience.
Hemab's work represents a pivotal moment for patients. For too long, individuals with VWD and GT have endured limited options. Hemophilia care has seen transformative prophylactic breakthroughs. Now, a similar paradigm shift is possible for other rare bleeding disorders. Hemab’s therapies offer hope for a future with fewer bleeds. They promise improved quality of life.
The capital investment positions Hemab for sustained growth. It empowers the company to accelerate clinical development. It facilitates the expansion of its therapeutic pipeline. This ensures a steady stream of advanced treatments. These innovations will address critical unmet medical needs. The ultimate goal remains clear: to transform lives.
Hemab’s journey highlights a critical area of medical innovation. Rare bleeding disorders demand specialized attention. They require dedicated research and development. This financing round reinforces that commitment. It signals a robust future for novel prophylactic treatments. It ensures more patients can access cutting-edge care.
This investment strengthens the biotechnology landscape. It underscores the value of targeted therapies. Companies like Hemab drive progress. They push boundaries in complex disease areas. Their efforts bring new solutions to challenging conditions. This round marks a significant milestone in that ongoing endeavor.
In summary, Hemab Therapeutics has secured substantial capital. This empowers it to lead in bleeding disorder therapeutics. It advances key programs like HMB-002 and sutacimig. It expands a promising pipeline. The company is poised to redefine care for underserved patient populations. This is a clear step towards becoming the ultimate clotting company.
Hemab Therapeutics announced a monumental $157 million Series C financing. This substantial funding propels the clinical-stage biotechnology company forward. It targets severe, underserved bleeding and thrombotic disorders. The round signals strong investor confidence in Hemab’s innovative pipeline.
Sofinnova Partners spearheaded the oversubscribed financing. A large long-only global asset management company also participated. New investors included a major global sovereign wealth fund and Avoro Capital Advisors. Existing investors reaffirmed their commitment. These included RA Capital Management, Novo Holdings, Access Biotechnology, and Deep Track Capital. HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital also contributed.
This strategic investment brings new leadership. Joe Anderson, PhD, Partner at Sofinnova Partners, joins Hemab’s Board. His expertise will guide the company’s trajectory. Benny Sorensen, MD, PhD, leads Hemab as CEO. He steers a company focused on novel prophylactic therapeutics. These solutions aim to transform treatment for patients facing significant unmet needs.
The immediate focus for the new capital is clear. Hemab will advance HMB-002. This program targets Von Willebrand Disease (VWD). The goal is to move HMB-002 towards registration studies. HMB-002 is an antibody-based treatment. Phase 1 data showed a clear mechanism of action. It directly addresses VWD’s underlying pathophysiology. It increases both Von Willebrand Factor and Factor VIII levels. This offers a novel approach, moving beyond symptom management.
Another critical program, sutacimig, will also benefit. Sutacimig treats Glanzmann thrombasthenia (GT). This rare disorder can be life-threatening. Hemab develops sutacimig as the first prophylactic therapy for GT. Promising Phase 2 results support its potential. The company plans a registration study in 2026. Further expansion into a Phase 2 study for Factor VII deficiency is also planned.
Hemab is not just advancing existing therapies. The company aims for broader pipeline expansion. It intends to introduce additional drug candidates. HMB-003 is one such program. Its announcement is expected in the first half of 2026. This reflects a commitment to a diverse portfolio. Hemab’s mission is to deliver innovative, durable treatment options.
The company’s development programs are deeply informed by patient experience. Hemab conducts natural history studies: GT360, FVIID360, and VWD360. These studies provide crucial insights. They reveal the profound physical and emotional burdens of chronic bleeding disorders. Such conditions have long lacked effective prophylactic therapies. Hemab’s approach is rooted in understanding these patient needs.
This significant funding round validates Hemab’s scientific rigor. It underscores its patient-centric approach. The biotech firm is building what it calls "the ultimate clotting company." This ambition involves leveraging unprecedented domain expertise in clotting science. It combines this with proven capabilities in drug development. From early stages to approval and commercialization, Hemab’s team brings extensive experience.
Hemab's work represents a pivotal moment for patients. For too long, individuals with VWD and GT have endured limited options. Hemophilia care has seen transformative prophylactic breakthroughs. Now, a similar paradigm shift is possible for other rare bleeding disorders. Hemab’s therapies offer hope for a future with fewer bleeds. They promise improved quality of life.
The capital investment positions Hemab for sustained growth. It empowers the company to accelerate clinical development. It facilitates the expansion of its therapeutic pipeline. This ensures a steady stream of advanced treatments. These innovations will address critical unmet medical needs. The ultimate goal remains clear: to transform lives.
Hemab’s journey highlights a critical area of medical innovation. Rare bleeding disorders demand specialized attention. They require dedicated research and development. This financing round reinforces that commitment. It signals a robust future for novel prophylactic treatments. It ensures more patients can access cutting-edge care.
This investment strengthens the biotechnology landscape. It underscores the value of targeted therapies. Companies like Hemab drive progress. They push boundaries in complex disease areas. Their efforts bring new solutions to challenging conditions. This round marks a significant milestone in that ongoing endeavor.
In summary, Hemab Therapeutics has secured substantial capital. This empowers it to lead in bleeding disorder therapeutics. It advances key programs like HMB-002 and sutacimig. It expands a promising pipeline. The company is poised to redefine care for underserved patient populations. This is a clear step towards becoming the ultimate clotting company.